Spero Therapeutics, Inc. (SPRO)
 NASDAQ: SPRO · Real-Time Price · USD
 2.360
 +0.030 (1.29%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Spero Therapeutics Employees
Spero Therapeutics had 32 employees as of December 31, 2024. The number of employees decreased by 14 or -30.43% compared to the previous year.
Employees 
 32
Change (1Y) 
 -14
Growth (1Y) 
 -30.43%
Revenue / Employee 
 $1,518,000
Profits / Employee 
 -$1,675,031
Market Cap 
132.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 32 | -14 | -30.43% | 
| Dec 31, 2023 | 46 | 11 | 31.43% | 
| Dec 31, 2022 | 35 | -111 | -76.03% | 
| Dec 31, 2021 | 146 | 57 | 64.04% | 
| Dec 31, 2020 | 89 | 32 | 56.14% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
SPRO News
- 10 days ago - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - GlobeNewsWire
- 16 days ago - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewsWire
- 2 months ago - Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 - GlobeNewsWire
- 5 months ago - Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results - Seeking Alpha
- 5 months ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
- 5 months ago - Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - GlobeNewsWire